Biologic tools to personalize treatment in genitourinary cancers

Critical Reviews in Oncology/Hematology

Volumn 84, Issue SUPPL. 1, 2012, Pages e42-e48

  Bracarda, Sergio ^a,b   Sisani, Michele ^a   Del Buono, Sabrina ^a   Ishiwa, Ori ^a   Montagnani, Francesco ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b AROME (Association of Radiotherapy and Oncology of the Mediterranean Area)   (Italy)

Author keywords

Predictive factors; Prognostic factors; Prostate cancer; Renal cell carcinoma; Urothelial cancer

Indexed keywords

ALPHA INTERFERON; AMINO TERMINAL TELOPEPTIDE; ANTHRACYCLINE; BCG VACCINE; BEVACIZUMAB; CD147 ANTIGEN; CHROMOGRANIN A; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EVEROLIMUS; FLUOROURACIL; INTERFERON; INTERLEUKIN 2; NEURON SPECIFIC ENOLASE; OSTEOPROTEGERIN; PAZOPANIB; PLATINUM COMPLEX; PROTEIN P53; SORAFENIB; SUNITINIB; SURVIVIN; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANTIANGIOGENIC ACTIVITY; BONE METASTASIS; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PLATELET MICROPARTICLE; PREDICTIVE VALUE; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT DISEASE;

EID: 84871676504     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.09.008     Document Type: Review

References (43)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Mills E.J., Rachlis B., O'Regan C., Thabane L., Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009, 9:34-39.
3. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(22):3584-3590.
4. Floyd E., McShane T.M. Development and use of biomarkers in oncology drug development. Toxicol Pathol 2004, 32(March-April (Suppl. 1)):106-115. [review].
5. Dowsett M., Procter M., McCaskill-Stevens W., et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol 2009, 27(18):2962-2969.
6. BIG 1-98 Collaborative Group, Mouridsen H., Giobbie-Hurder A., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361(August (8)):766-776.
7. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-months analysis of the ATAC trial. Lancet Oncol 2008, 9(1):45-53. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.
8. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(September 25-October 1 (9440)):1127-1134.
9. Rajpar S., Massard C., Laplanche A., et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol 2010, 21(9):1864-1869.
10. Chung H.C., Bang Y., Van Cutsem E., et al. (Q)-TwiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER-2positive gastric cancer. J Clin Oncol 2010, 28. 15s [abstr 4048].
11. Domingo-Domenech J., Fernandez P.L., Filella X., et al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 2008, 19(2):269-275.
12. Gennari A., Sormani M.P., Pronzato P., et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100(1):14-20.
13. Che M., DeSilvio M., Pollack A., et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int J Radiat Oncol Biol Phys 2007, 69(4):1117-1123.
14. Helley D., Banu E., Bouziane A., et al. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 2009, 56(3):479-484.
15. Eaton C.L., Wells J.M., Holen I., Croucher P.I., Hamdy F.C. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004, 59(3):304-310.
16. Chan L.W., Moses M.A., Goley E., et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004, 22(3):499-506.
17. Berruti A., Mosca A., Porpiglia F., et al. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. J Urol 2007, 178(3 Pt 1):838-843.
18. Kamiya N., Akakura K., Suzuki H., et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003, 44(3):309-314.
19. Bork R.A., Halabi S., Fei D.T., et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001, 61(6):2533-2536.
20. Haas N.B., Uzzo R.G. Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options Oncol 2007, 8(3):211-226.
21. Bracarda S., Porta C., Boni C., et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681. ASCO Genitourinary Cancers Symposium 2008, [abstract 357].
22. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281.
23. Vaziri S.A., Kim J., Ganapathi M.K., Gnapathi R. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 2010, 12(2):102-108.
24. Choueiri T.K., Regan M.M., Rosenberg J.E., et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010, 106(6):772-778.
25. Porta C., Paglino C., De Amici M., et al. Predictive value of baseline serum vascular andothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77(9):755-757.
26. Perez-Gracia J.L., Prior C., Guillén-Grima F., et al. Identification of TNF-alpha and MMP-9 as potential predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009, 101(11):1876-1883.
27. Jeppesen A.N., Jensen H.K., Donskov F., Marcussen N., von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010, 102(5):867-872.
28. Westermann J., Hecker A.C., Flörcken A., Dörken B., Pezzutto A. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome. J Immunother 2009, 32(6):667-675.
29. Miyake H., Sakai I., Muramaki M., et al. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol 2009, 16(5):465-471.
30. Sabatino M., Kim-Schulze S., Panelli M.C., et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009, 27(16):2645-2652.
31. Bellmunt J., Albiol S., Suarez C., Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Hematol Oncol 2009, 69(March (3)):211-222.
32. Matsumoto H., Matsuyama H., Fukunaga K., Yoshihiro S., Wada T., Kaito K. Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer. Br J Cancer 2004, 91(6):1025-1031.
33. Pinho M.B., Costas F., Sellos J., et al. XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. Urol Oncol 2009, 27(4):382-390.
34. Yutkin V., Pode D., Pikarsky E., Mandelboim O. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. J Urol 2007, 178(6):2660-2664.
35. Avari C., LaRue H., Hovington H., et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol 2009, 55(6):1386-1395.
36. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18(3):522-528.
37. Kitamura H., Torigoe T., Honma I., et al. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer. Clin Cancer Res 2006, 12(15):4641-4644.
38. Lebret T., Watson R.W., Molinié V., et al. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur Urol 2007, 51(1):161-166.
39. Matsumoto H., Wada T., Fukunaga K., Yoshihiro S., Matsuyama H., Naito K. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 2004, 34(3):124-130.
40. Garcia del Muro X., Condom E., Vigues F., et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004, 100(9):1859-1867.
41. Riethdorf S., Muller V., Zhang L., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16(9):2634-2645.
42. Scher H.I., Jia X., de Bono J.S., et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10(3):233-239.
43. Lin H., Balic M., Zheng S., Datar R., Cote R.J. Disseminated and circulating tumor cells: role in effective cancer management. Crit Rev Oncol Hematol 2010, [Epub ahead of print].